Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survivin 2B siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
Survivin 2B siRNA (also known as 2B-siRNA) is an experimental RNA interference (RNAi) therapeutic designed to specifically silence the survivin 2B splice variant, an isoform of the BIRC5 gene. Survivin 2B is a proto-oncogene that promotes cell cycle progression and confers resistance to apoptosis. Preclinical research has primarily investigated its potential in treating taxane-resistant ovarian cancer, where the variant is significantly overexpressed compared to taxane-sensitive cells. It has also been studied in the context of rheumatoid arthritis, where it is upregulated in fibroblast-like synoviocytes. The compound is typically formulated with DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) nanoliposomes for in vivo delivery and has demonstrated significant tumor growth reduction in orthotopic murine models, particularly when used in combination with docetaxel chemotherapy. It is currently a research tool used in academic settings and has no identified commercial developer or brand name.
- Other names
- survivin 2B small interfering RNAsurvivin2B small interfering RNAsurvivin-2B small interfering RNA
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on survivin 2B siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survivin 2B siRNA.